Kern Wolfgang, Danhauser-Riedl Susanne, Ratei Richard, Schnittger Susanne, Schoch Claudia, Kolb Hans-Jochem, Ludwig Wolf-Dieter, Hiddemann Wolfgang, Haferlach Torsten
Laboratory for Leukemia Diagnostics, Ludwig-Maximilians-University, University Hospital Grosshadern, Dept. of Internal Medicine III, Muenchen, Germany
Haematologica. 2003 Jun;88(6):646-53.
Detection of minimal residual disease (MRD) by multiparameter flow cytometry is an emerging prognostic factor in patients with acute myeloid leukemia (AML). The present analysis aimed at improving the applicability of this approach to more patients with AML.
Bone marrow samples from unselected patients with AML at diagnosis and from healthy volunteers were immunophenotyped applying triple-stainings of 31 antigens. Leukemia-associated immunophenotypes were defined by gating on populations displaying an aberrant or infrequent immunophenotype and by applying Boolean algebra. The combination of gates obtained was applied to list mode data files containing measurements of normal bone marrow samples. Dilution experiments of AML samples in normal bone marrow were performed to test the linearity of measurements.
At least one aberrant/infrequent immunophenotype was identified (median, 2; range, 1-5) in all of 68 analyzed AML patients. The median frequencies of cells displaying an aberrant/infrequent immunophenotype within normal bone marrow ranged from 0.00% to 1.20% (median, 0.07%). Limiting this analysis to only the most sensitive aberrant/infrequent immunophenotype per patient resulted in frequencies of cells displaying an aberrant/infrequent immunophenotype within normal bone marrow ranging from 0.00% to 0.43% (median, 0.05%). Serial dilution experiments confirmed the linearity of measurements (R>0.90 in all cases analyzed).
The application of multiparameter flow cytometry to identify cells displaying an aberrant/infrequent immunophenotype and to quantify MRD is feasible in unselected patients with AML.
通过多参数流式细胞术检测微小残留病(MRD)是急性髓系白血病(AML)患者中一种新兴的预后因素。本分析旨在提高这种方法在更多AML患者中的适用性。
对未经选择的AML诊断患者和健康志愿者的骨髓样本进行31种抗原的三重染色免疫表型分析。通过对显示异常或罕见免疫表型的细胞群进行门控并应用布尔代数来定义白血病相关免疫表型。将获得的门控组合应用于包含正常骨髓样本测量值的列表模式数据文件。进行AML样本在正常骨髓中的稀释实验以测试测量的线性。
在68例分析的AML患者中,所有患者均鉴定出至少一种异常/罕见免疫表型(中位数为2;范围为1 - 5)。在正常骨髓中显示异常/罕见免疫表型的细胞的中位数频率范围为0.00%至1.20%(中位数为0.07%)。将分析仅限于每位患者最敏感的异常/罕见免疫表型,导致正常骨髓中显示异常/罕见免疫表型的细胞频率范围为0.00%至0.43%(中位数为0.05%)。系列稀释实验证实了测量的线性(所有分析病例中R>0.90)。
在未经选择的AML患者中,应用多参数流式细胞术识别显示异常/罕见免疫表型的细胞并定量MRD是可行的。